Kathryn Greven to Disease-Free Survival
This is a "connection" page, showing publications Kathryn Greven has written about Disease-Free Survival.
Connection Strength
0.388
-
Garg S, Kilburn JM, Lucas JT, Randolph D, Urbanic JJ, Hinson WH, Kearns WT, Porosnicu M, Greven K. Reirradiation for second primary or recurrent cancers of the head and neck: Dosimetric and outcome analysis. Head Neck. 2016 04; 38 Suppl 1:E961-9.
Score: 0.109
-
Saconn PA, Gee CJ, Greven CM, McCoy TP, Ekstrand KE, Greven KM. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):844-8.
Score: 0.075
-
Greven KM, White DR, Browne JD, Williams DW, McGuirt WF, D'Agostino RB. Swallowing dysfunction is a common sequelae after chemoradiation for oropharynx carcinoma. Am J Clin Oncol. 2008 Jun; 31(3):209-12.
Score: 0.066
-
Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):111-7.
Score: 0.061
-
Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006 Oct; 103(1):155-9.
Score: 0.057
-
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011 Feb; 21(2):419-23.
Score: 0.020